Compare Stocks: CGEM, EWTX, ABCL, and RLAY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.00 -6.5%	$11.13	$2.74 ▼ $15.02	$3.68B	1.41	6.09 million shs	3.04 million shs
CGEM Cullinan Therapeutics	$14.94 -4.4%	$19.45	$6.50 ▼ $23.19	$961.22M	-0.05	908,417 shs	175,732 shs
EWTX Edgewise Therapeutics	$37.92 -4.2%	$42.89	$14.25 ▼ $48.51	$4.11B	0.35	1.24 million shs	277,912 shs
RLAY Relay Therapeutics	$16.92 -5.7%	$19.12	$5.85 ▼ $21.27	$3.71B	1.72	3.19 million shs	674,842 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-2.43%	-12.06%	+12.25%	+75.99%	+122.36%
CGEM Cullinan Therapeutics	-3.82%	+1.82%	-29.24%	-14.96%	+165.37%
EWTX Edgewise Therapeutics	-1.12%	-2.83%	-8.13%	-18.16%	+161.36%
RLAY Relay Therapeutics	-4.22%	-0.55%	-5.72%	-13.49%	+207.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.00 -6.5%	$11.13	$2.74 ▼ $15.02	$3.68B	1.41	6.09 million shs	3.04 million shs
CGEM Cullinan Therapeutics	$14.94 -4.4%	$19.45	$6.50 ▼ $23.19	$961.22M	-0.05	908,417 shs	175,732 shs
EWTX Edgewise Therapeutics	$37.92 -4.2%	$42.89	$14.25 ▼ $48.51	$4.11B	0.35	1.24 million shs	277,912 shs
RLAY Relay Therapeutics	$16.92 -5.7%	$19.12	$5.85 ▼ $21.27	$3.71B	1.72	3.19 million shs	674,842 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-2.43%	-12.06%	+12.25%	+75.99%	+122.36%
CGEM Cullinan Therapeutics	-3.82%	+1.82%	-29.24%	-14.96%	+165.37%
EWTX Edgewise Therapeutics	-1.12%	-2.83%	-8.13%	-18.16%	+161.36%
RLAY Relay Therapeutics	-4.22%	-0.55%	-5.72%	-13.49%	+207.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$13.38	11.48% Upside
CGEM Cullinan Therapeutics	2.78	Moderate Buy	$33.71	125.69% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$51.33	35.36% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	53.16% Upside

Current Analyst Ratings Breakdown

Latest CGEM, EWTX, ABCL, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	CGEM Cullinan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/2/2026	RLAY Relay Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/2/2026	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
9/29/2026	ABCL AbCellera Biologics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$17.00
9/25/2026	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $35.00
9/25/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/24/2026	ABCL AbCellera Biologics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00
9/21/2026	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $57.00
9/14/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/24/2026	CGEM Cullinan Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00

(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	48.96	N/A	N/A	$3.23 per share	3.71
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$6.92 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
RLAY Relay Therapeutics	$15.35M	241.57	N/A	N/A	$3.27 per share	5.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/9/2026 (Confirmed)
CGEM Cullinan Therapeutics	-$219.88M	-$3.10	N/A	N/A	N/A	N/A	-52.89%	-48.18%	11/5/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)

Latest CGEM, EWTX, ABCL, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	CGEM Cullinan Therapeutics	-$0.8435	N/A	N/A	N/A	$2.00 million	N/A
11/5/2026	Q3 2026	EWTX Edgewise Therapeutics	-$0.5335	N/A	N/A	N/A	$129.17 million	N/A
11/5/2026	Q3 2026	RLAY Relay Therapeutics	-$0.40	N/A	N/A	N/A	$1.62 million	N/A
8/6/2026	Q2 2026	CGEM Cullinan Therapeutics	-$0.7993	-$0.81	-$0.0107	-$0.81	$3.67 million	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
CGEM Cullinan Therapeutics	N/A	8.42	8.42
EWTX Edgewise Therapeutics	N/A	16.24	16.24
RLAY Relay Therapeutics	N/A	18.27	18.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CGEM Cullinan Therapeutics	86.31%
EWTX Edgewise Therapeutics	N/A
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
CGEM Cullinan Therapeutics	8.60%
EWTX Edgewise Therapeutics	21.30%
RLAY Relay Therapeutics	5.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	562	306.61 million	219.53 million	Optionable
CGEM Cullinan Therapeutics	109	64.36 million	58.82 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable

CGEM, EWTX, ABCL, and RLAY Headlines

Recent News About These Companies

Krystal Biotech (NASDAQ:KRYS) and Relay Therapeutics (NASDAQ:RLAY) Head-To-Head Survey

October 8 at 6:15 AM | americanbankingnews.com

Congress Asset Management Co. Raises Position in Relay Therapeutics, Inc. $RLAY

October 7 at 3:20 AM | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Has Consensus Price Target of $25.92 According to Brokerages

September 28, 2026 | americanbankingnews.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 28, 2026 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Shares Down 8.8% - What's Next?

September 23, 2026 | marketbeat.com

Relay Therapeutics stock holds near its Nasdaq quote

September 22, 2026 | ad-hoc-news.deA

Bank of America Corp DE Invests $50.42 Million in Relay Therapeutics, Inc. $RLAY

September 21, 2026 | marketbeat.com

Relay Therapeutics stock consolidates after recent gains as investors watch pipeline progress

September 20, 2026 | ad-hoc-news.deA

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Squarepoint Ops LLC Has $1.74 Million Position in Relay Therapeutics, Inc. $RLAY

September 16, 2026 | marketbeat.com

Wellington Management Group LLP Has $2.94 Million Stock Position in Relay Therapeutics, Inc. $RLAY

September 11, 2026 | marketbeat.com

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

September 10, 2026 | seekingalpha.com

Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 8,530 Shares of Stock

September 10, 2026 | insidertrades.com

Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 8,530 Shares of Stock

September 9, 2026 | marketbeat.com

Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 17,717 Shares of Stock

September 9, 2026 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) CEO Sanjiv Patel Sells 48,199 Shares of Stock

September 9, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in Relay Therapeutics, Inc. $RLAY

September 9, 2026 | marketbeat.com

Relay Therapeutics CFO Sells 17,717 Shares for $350,000

September 2, 2026 | fool.com

Relay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside Chats

September 1, 2026 | quiverquant.comQ

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

September 1, 2026 | globenewswire.com

Peter Rahmer Sells 4,508 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

August 29, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, EWTX, ABCL, and RLAY Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$12.00 -0.83 (-6.48%)

As of 11:44 AM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Cullinan Therapeutics NASDAQ:CGEM

$14.94 -0.69 (-4.43%)

As of 11:44 AM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Edgewise Therapeutics NASDAQ:EWTX

$37.92 -1.65 (-4.16%)

As of 11:44 AM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Relay Therapeutics NASDAQ:RLAY

$16.92 -1.03 (-5.73%)

As of 11:44 AM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGEM, EWTX, ABCL, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGEM, EWTX, ABCL, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGEM, EWTX, ABCL, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, EWTX, ABCL, and RLAY Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Cullinan Therapeutics NASDAQ:CGEM

Edgewise Therapeutics NASDAQ:EWTX

Relay Therapeutics NASDAQ:RLAY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGEM, EWTX, ABCL, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGEM, EWTX, ABCL, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGEM, EWTX, ABCL, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, EWTX, ABCL, and RLAY Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Cullinan Therapeutics NASDAQ:CGEM

Edgewise Therapeutics NASDAQ:EWTX

Relay Therapeutics NASDAQ:RLAY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools